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Background: Sore throat caused by Streptococcus pyogenes
group A (Strep A) may warrant antibiotic treatment due to risk
of complications. Other Streptococci (group C) have been associ-
ated with sore throat but there is insufﬁcient evidence that they
cause complications.Weevaluateddisease severity inpatientswith
streptococcal and non-streptococcal sore throat, and the effect of
ﬂurbiprofen 8.75mg lozenge on symptoms prior to any antibiotic
administration.
Methods & Materials: Adults with sore throat <4 days were
evaluated for ﬁndings of pharyngitis using the Tonsillo-Pharyngitis
Assessment (TPA) and pharyngeal inﬂammation using the Prac-
titioner’s Assessment of Inﬂammation and randomly assigned
ﬂurbiprofen or placebo lozenges under double-blind conditions.
They rated their sore throat pain on the Throat Pain Scale and
pain on swallowing (odynophagia) on the Sore Throat Pain Inten-
sity Scale (STPIS) at baseline and over 7 days. Antibiotics could be
administrated at the investigator’s discretion once a diagnosis was
made by throat culture (at ∼48hours).
Results: Of 204 patients, 32 (16%) had Strep A and 52 (25%)
had Strep C. Both types of Strep patients had similar physical fea-
tures, although pharyngeal inﬂammation was slightly more severe
for Strep A (18.8%) than Strep C and non-Strep patients (11.5% and
11.7%, respectively, bothp=NS). 62.5%of StrepApatients described
relativelymore severeodynophagia comparedwith34.6%of StrepC
(p<0.05) and 44.2% of non-Strep patients (p =0.064). Themean TPA
scores were similar irrespective of cause, indicating the difﬁculty
in making a diagnosis based on physical ﬁndings. Irrespective of
cause, patients taking ﬂurbiprofen lozenges reported -473.7 mm*h
decrease in STPIS scores over the ﬁrst (pre-antibiotic) 24hours
compared with -322.3 mm*h on placebo (i.e. 47% more relief with
ﬂurbiprofen versus placebo, p <0.05). By 48hours, mean lozenge
consumption per day had decreased in both treatment groups
regardless of etiology, indicating the natural resolution of symp-
toms with time.
Conclusion: Patients with Strep A appear to have more
severe pain and inﬂammation than those with Strep C or non-
streptococcal infection, although their clinical features are not
distinct on physical examination. Sore throat, irrespective of cause,
is a self-limiting condition but symptoms beneﬁt from treatment
with ﬂurbiprofen lozenge.
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A novel mechanism of host cell death by ESAT-6
like protein of Mycobacterium tuberculosis
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Background:Mycobacterium tuberculosis (Mtb), causative agent
of human tuberculosis (TB), manipulates the host immune
responses for its survival. Several secretary proteins exported
through ESX secretion system modulate the antibacterial effector
functions ofmacrophages.Hereweattempted to functionally eluci-
date the roleof oneof thepreviouslyuncharacterizedESAT-6 family
protein in Mtb pathogenesis.
Methods & Materials: Mtbgene is cloned and expressed
inMycobacterium smegmatis. Invasion assay is performed in HeLa
cells where as survival assays were carried out in both mouse and
human macrophages. Survival mechanisms were studied by quan-
tifying free radicals formation and host survival rate. Induction of
autophagic pathway is studiedby the expression of LC3. Nuclear
and chromosomal aberrations were studied using micronucleus
assay. The level of cytokine expressionsweremeasuredusing qPCR.
Results:RecombinantMycobacterium smegmatis strain express-
ing ESAT-6 family protein showed more invasion in human
epithelial cells (HeLa) and survival in mouse macrophages
(RAW264.7) and human monocyte derived macrophages (THP-
1). The survival mechanistic studies revealed, infection induced
host cell death and also up regulation of the level of nitric oxide,
induciblenitric oxide synthase, reactiveoxygenspecies, superoxide
dismutase and catalase activities. Moreover, Mycobacterium smeg-
matis expressing ESAT-6 infection reduced T-cell survival, caused
loss of mitochondrial membrane integrity, activated autophagy
and also induced the expression of NF-	B and late endosomal
markers such as Rab10, LAMP-2, Cathepsin-B and Cathepsin-Z in
macrophages. An up regulation of both pro-inﬂammatory (TNF-
, IL-12) and anti-inﬂammatory (IL-10, TGF-) cytokines was
also observed after infection in macrophages. Genome stability
studies showed that recombinant Mycobacterium smegmatis strain
expressing ESAT-6 family protein infection led to several chromo-
somal abnormalities such as micronuclei formation in cytokinesis
blocked cells, chromosomal malsegregation and nuclear fragmen-
tation.
Conclusion: We envision that this study offers a novel mecha-
nism of host cell death by Mtb infection. Taken together, this study
has identiﬁed a novel ESAT-6 like family protein that acts as viru-
lence as well as an immunomodulatory factor to evade killing by
host, and thus it may provide a novel drug target.
http://dx.doi.org/10.1016/j.ijid.2014.03.1155
